Quick answer
How do incretin and amylin research peptides differ? Semaglutide acts on the GLP-1 receptor; tirzepatide on both the GIP and GLP-1 receptors; retatrutide on GIP, GLP-1 and glucagon receptors; and cagrilintide on amylin and calcitonin receptors. They are compared in the laboratory by receptor selectivity, signaling bias, half-life engineering (fatty-acid acylation and albumin binding) and the readouts used, such as cAMP accumulation in receptor-expressing cells, insulin secretion in islets and food-intake or metabolic measurements in rodents. Reviews summarize the biology (Drucker, 2018; Müller and colleagues, 2019) and the primary papers describe each molecule's design. All data here are preclinical or chemical; no human-use claims are made. For laboratory research use only.
Metabolic-signaling peptides are the most heavily searched category in the research peptide field, and the one most prone to loose language. This article stays with receptor pharmacology and laboratory models. It organizes four compounds by the receptors they engage, explains how each was engineered, and sets out the assays used to tell them apart. Product details are taken from the live catalog pages, and all material is supplied for laboratory research use only; not for human consumption.
Receptor map
| Compound | Receptors engaged | Class | Product page |
|---|---|---|---|
| Semaglutide | GLP-1 receptor | Acylated GLP-1 analog | Semaglutide |
| Tirzepatide | GIP receptor and GLP-1 receptor | Dual agonist peptide | Tirzepatide |
| Retatrutide | GIP, GLP-1 and glucagon receptors | Triple agonist peptide | Retatrutide |
| Cagrilintide | Amylin and calcitonin receptors | Acylated amylin analog | Cagrilintide |
Receptor basics are explained in incretin receptors explained and the class overview is in GLP-1 receptor agonists in research.
The biology of the incretin system
Drucker (2018) reviews the mechanisms of GLP-1: a gut-derived hormone that potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and acts on central circuits that regulate appetite. Native GLP-1 is cleared within minutes by the enzyme dipeptidyl peptidase-4 and by the kidney, so research analogs are designed to resist degradation and extend half-life. Müller and colleagues (2019) provide a broad review of the GLP-1 field, including receptor distribution and signaling. For a laboratory the practical significance is that GLP-1 receptor signaling is read out through cAMP in receptor-expressing cells and through insulin secretion in islets, before any whole-animal work.
Engineering for duration
Semaglutide's design is described by Lau and colleagues (2015): amino acid substitutions that protect against DPP-4 cleavage plus a fatty diacid side chain attached through a linker, which promotes albumin binding and slows clearance. Cagrilintide follows a related logic for amylin. Kruse and colleagues (2021) describe how the amylin backbone was modified and acylated to achieve long action and to address the aggregation tendency of native amylin. Both are examples of lipidation, a strategy that changes how a peptide behaves on the bench as well as in vivo, because acylated peptides adsorb to surfaces and self-associate more readily. That matters for handling and is discussed in semaglutide reconstitution and handling and the cagrilintide overview.
Dual and triple agonists
Coskun and colleagues (2018) describe the discovery of tirzepatide, a single peptide with agonist activity at both GIP and GLP-1 receptors, and report its receptor-level pharmacology: stronger activity at the GIP receptor than at the GLP-1 receptor in their cell assays, and biased signaling at the GLP-1 receptor. In 2022 the same group described the triple agonist retatrutide, which adds glucagon receptor agonism. These papers show how receptor-level pharmacology is characterized: cells expressing one human receptor at a time, cAMP or beta-arrestin readouts, concentration-response curves and comparison with the native hormone. Reading a paper on a multi-receptor agonist means checking each receptor's potency separately and noting the assay system, since potency in an overexpressing cell line may not match that in native tissue. Comparisons within the library: semaglutide versus tirzepatide, retatrutide versus tirzepatide and cagrilintide versus tirzepatide.
Assays that distinguish them
| Assay | What it tells you | Limit |
|---|---|---|
| cAMP accumulation in receptor-expressing cells | Potency and efficacy at each receptor | Overexpression can exaggerate potency |
| Beta-arrestin recruitment | Signaling bias between pathways | Different assay formats give different bias values |
| Islet insulin secretion at low and high glucose | Glucose dependence of the response | Islet-to-islet variability |
| Receptor binding with and without albumin | Effect of acylation on apparent affinity | Albumin source and concentration change the result |
| Rodent metabolic phenotyping | Whole-organism integration of the receptors | Species differences; many confounders |
The albumin row is a trap worth noting. Acylated peptides bind albumin strongly, so their apparent potency in a serum-containing medium is lower than in a serum-free one. Comparing a lipidated and a non-lipidated peptide without controlling albumin gives a misleading ranking.
A short comparison of study designs
- Single-receptor characterization. One receptor per cell line, full concentration-response, native hormone as reference.
- Selectivity panel. The same compound across GLP-1, GIP, glucagon, amylin and calcitonin receptors, to show cross-reactivity.
- Matched-exposure comparison. Compounds compared at equal molar concentrations, with albumin held constant.
- Stability study. HPLC-tracked integrity under defined storage conditions.
Reading potency numbers across papers
A frequent error is to line up potency values from different publications in one table and rank the compounds. Potency is expressed as an EC50, the concentration giving half the maximal response, and it depends on receptor expression level, the cell background, the assay format, the incubation time and the presence of albumin or serum. Two EC50 values from different laboratories can differ by an order of magnitude for the same molecule. A fair comparison uses a single study in which all compounds were run in parallel with the native ligand as an internal reference, and reports ratios to that reference rather than raw numbers. Efficacy matters as well as potency: a partial agonist may reach a lower maximum than the native hormone even at saturating concentration, which a potency number alone hides.
Signaling bias adds another layer. A ligand can favor cAMP production over beta-arrestin recruitment at the same receptor, and the balance varies with the assay used to measure it. Papers that describe bias should state the reference ligand and the method for calculating it, since different calculation approaches give different values. The tirzepatide work by Coskun and colleagues illustrates this: reported bias at the GLP-1 receptor was defined relative to the native hormone in a specific cell system.
Stability and aggregation as experimental variables
Long-acting peptides are designed to survive in the body, but on the bench they face different threats. Amylin-derived peptides have an inherent tendency to form fibrils, and acylation adds a hydrophobic tail that promotes micelle-like association. Aggregated material is less active in a receptor assay and can scatter light or clog filters, so a stock solution that is cloudy or has visible strands should not be used. Freeze-thaw cycles, vigorous agitation and long storage in solution are the usual triggers. The simplest safeguard is to divide a stock into single-use portions, keep them cold and use an HPLC trace or a light-scattering check when concentration or integrity is critical. The related questions of vial appearance and cloudiness are covered in peptide vial appearance: what is normal and cloudy peptide vial after reconstitution.
Choosing a compound for a receptor question
| Question | Suitable reagent | Comment |
|---|---|---|
| Isolating GLP-1 receptor signaling | Semaglutide, with a GLP-1 receptor antagonist as a control | Single-receptor agonist among the four |
| Testing GIP and GLP-1 co-activation | Tirzepatide, with single-receptor antagonists | Distinguishing the contribution of each receptor needs blocking each in turn |
| Adding glucagon receptor to the picture | Retatrutide | Three receptors; interpretation requires a full antagonist panel |
| Amylin receptor biology | Cagrilintide | Different receptor family; amylin receptors are complexes of the calcitonin receptor with RAMP proteins |
Handling lipidated and large peptides
Lipidated peptides call for careful handling: low-binding plasticware, gentle swirling rather than shaking, and avoiding repeated freeze-thaw cycles, in line with general stability principles (Manning and colleagues, 2010; Goebel-Stengel and colleagues, 2011). The product pages state storage at 2–8 °C with −20 °C for long-term, away from heat, moisture and light. Concentration is vial mass divided by diluent volume, and molarity is that divided by molecular weight; the reconstitution calculator does the arithmetic and how to reconstitute a lyophilized peptide gives the technique. Certificates are in the COA library where published, and how to read a COA explains the fields. The overall comparison article is semaglutide, tirzepatide, retatrutide and cagrilintide compared. The full range is at /shop.
What these papers do not tell you
Receptor pharmacology describes a molecule's behavior in a defined system. It does not predict whole-organism outcomes, and rodent results do not carry over automatically to other species. A reader should also keep in mind that potency numbers from different laboratories, cell lines and assay formats are not directly comparable. The responsible way to rank compounds is within a single experiment, run under identical conditions, with the same reference ligand and the same albumin level.
Frequently asked questions
What is the main difference between semaglutide and tirzepatide?
Semaglutide acts on the GLP-1 receptor. Tirzepatide is a single peptide that acts on both the GIP and GLP-1 receptors, as described by Coskun and colleagues in 2018.
What does retatrutide add?
Agonist activity at the glucagon receptor in addition to GIP and GLP-1, as reported in a 2022 discovery paper from the group that developed it.
How does cagrilintide differ?
It is an acylated amylin analog acting on amylin and calcitonin receptors, a different receptor family from the incretin receptors.
Why are these peptides acylated?
A fatty acid side chain promotes albumin binding and slows clearance, extending half-life. It also changes bench behavior, increasing adsorption and self-association.
How is receptor potency measured?
Commonly by cAMP accumulation in cells that express one receptor, with full concentration-response curves and the native hormone as a reference.
Why does albumin matter in assays?
Acylated peptides bind albumin, so apparent potency falls in serum-containing medium. Comparisons must keep albumin constant.
Do cell potency values predict animal outcomes?
Not reliably. Overexpressing cell lines can exaggerate potency, and species and tissue differences add further uncertainty.
How should lipidated peptides be handled?
Use low-binding plasticware, swirl instead of shaking, avoid repeated freeze-thaw cycles and record the lot number.
How are the vials stored?
Product pages state 2–8 °C, with −20 °C for long-term storage, protected from heat, moisture and light.
Where can certificates be checked?
In the COA library, where a certificate is published for the lot.
Related reading: GLP-1 Peptides Compared: Receptors and Assay Choice.
References
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
- Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
- Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Goebel-Stengel M, Stengel A, Tache Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
